Ocugen CEO to Present at NobleCon20 – Noble Capital Markets’ 20th Annual Emerging Growth Equity Conference
Ocugen (NASDAQ: OCGN) announced that Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder, will present at NobleCon20 – Noble Capital Markets' 20th Annual Emerging Growth Equity Conference. The presentation is scheduled for December 3, 2024, at 1:30 p.m. ET at Florida Atlantic University in Boca Raton, FL.
The event will feature a presentation and moderated Q&A session, where Dr. Musunuri will provide updates on Ocugen's clinical programs. The company's executive team will also conduct one-on-one meetings with investors to discuss their business and clinical development strategy for their modifier gene therapy platform.
A video webcast will be available the following day on Ocugen's website, Noble Capital Markets' Conference website, and Channelchek, remaining accessible for 90 days.
Ocugen (NASDAQ: OCGN) ha annunciato che il Dr. Shankar Musunuri, Presidente, CEO e Co-Fondatore, presenterà al NobleCon20 – XX Conferenza Annuale di Crescita Emergente di Noble Capital Markets. La presentazione è prevista per il 3 dicembre 2024, alle 13:30 ET presso la Florida Atlantic University a Boca Raton, FL.
L'evento includerà una presentazione e una sessione di domande e risposte moderata, durante la quale il Dr. Musunuri fornirà aggiornamenti sui programmi clinici di Ocugen. Anche il team esecutivo dell'azienda condurrà incontri individuali con gli investitori per discutere della loro strategia aziendale e di sviluppo clinico per la loro piattaforma di terapia genica modificatrice.
Un video della presentazione sarà disponibile il giorno successivo sul sito web di Ocugen, sul sito della conferenza di Noble Capital Markets e su Channelchek, rimanendo accessibile per 90 giorni.
Ocugen (NASDAQ: OCGN) anunció que el Dr. Shankar Musunuri, Presidente, CEO y Co-Fundador, presentará en el NobleCon20 – Conferencia Anual de Crecimiento Emergente número 20 de Noble Capital Markets. La presentación está programada para el 3 de diciembre de 2024, a la 1:30 p.m. ET en la Universidad Atlantic de Florida en Boca Raton, FL.
El evento contará con una presentación y una sesión de preguntas y respuestas moderada, donde el Dr. Musunuri ofrecerá actualizaciones sobre los programas clínicos de Ocugen. El equipo ejecutivo de la empresa también llevará a cabo reuniones individuales con inversores para discutir su estrategia de negocio y desarrollo clínico para su plataforma de terapia génica modificadora.
Un video de la presentación estará disponible al día siguiente en el sitio web de Ocugen, en el sitio de la Conferencia de Noble Capital Markets y en Channelchek, y será accesible durante 90 días.
Ocugen (NASDAQ: OCGN)는 Shankar Musunuri 박사가 NobleCon20 – Noble Capital Markets의 제20회 연례 신흥 성장 주식 회의에서 발표할 것이라고 발표했습니다. 발표는 2024년 12월 3일 오후 1시 30분 ET에 플로리다 애틀랜틱 대학교에서 진행됩니다.
이번 행사에서는 Musunuri 박사가 Ocugen의 임상 프로그램에 대한 업데이트를 제공하는 발표와 진행된 Q&A 세션이 포함됩니다. 회사의 경영진 팀은 또한 투자자와의 일대일 회의를 통해 비즈니스 및 임상 개발 전략에 대해 논의합니다.
발표 영상은 다음 날 Ocugen의 웹사이트, Noble Capital Markets의 회의 웹사이트 및 Channelchek에서 이용할 수 있으며, 90일 동안 접근 가능합니다.
Ocugen (NASDAQ: OCGN) a annoncé que Dr. Shankar Musunuri, Président, CEO et Co-Fondateur, présentera à NobleCon20 – la 20e Conférence Annuelle sur les Actions en Croissance Émergente de Noble Capital Markets. La présentation est prévue pour le 3 décembre 2024, à 13h30 ET à l’Université Atlantic de Floride à Boca Raton, FL.
L'événement comportera une présentation et une session de questions-réponses modérée, où Dr. Musunuri fournira des mises à jour sur les programmes cliniques d'Ocugen. L'équipe exécutive de la société réalisera également des réunions individuelles avec les investisseurs pour discuter de leur stratégie commerciale et de développement clinique pour leur plateforme de thérapie génique modifiée.
Un enregistrement vidéo sera disponible le lendemain sur le site Web d'Ocugen, sur le site de la conférence de Noble Capital Markets et sur Channelchek, et restera accessible pendant 90 jours.
Ocugen (NASDAQ: OCGN) gab bekannt, dass Dr. Shankar Musunuri, Vorsitzender, CEO und Mitbegründer, auf der NobleCon20 – der 20. jährlichen Emerging Growth Equity Conference von Noble Capital Markets – präsentieren wird. Die Präsentation ist für den 3. Dezember 2024 um 13:30 Uhr ET an der Florida Atlantic University in Boca Raton, FL, geplant.
Die Veranstaltung wird eine Präsentation und eine moderierte Frage-und-Antwort-Runde umfassen, in der Dr. Musunuri Updates zu den klinischen Programmen von Ocugen geben wird. Das Führungsteam des Unternehmens wird auch Einzelgespräche mit Investoren führen, um deren Geschäfts- und klinische Entwicklungsstrategie für ihre modifizierte Gentherapie-Plattform zu besprechen.
Ein Video-Streaming wird am folgenden Tag auf der Website von Ocugen, der Konferenz-Website von Noble Capital Markets und Channelchek verfügbar sein und bleibt 90 Tage lang zugänglich.
- None.
- None.
MALVERN, Pa., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder of Ocugen will present at NobleCon20 – Noble Capital Markets’ 20th Annual Emerging Growth Equity Conference at Florida Atlantic University, Executive Education Complex, in Boca Raton, FL—taking place December 3 - 4, 2024.
“Every year, NobleCon showcases emerging growth companies from a variety of industries to a relevant investor audience,” said Dr. Musunuri. “I look forward to sharing an update on our clinical programs for attendees who may not yet be familiar with the Ocugen story.”
Details regarding the presentation and moderated Q&A are as follows:
Date: Tuesday, December 3, 2024
Location: Presentation Room 3
Time: 1:30 p.m. ET
In addition to Dr. Musunuri’s session, members of Ocugen’s executive team will conduct one-on-one meetings with investors to highlight the Company’s business and clinical development strategy across its unique modifier gene therapy platform.
A high-definition video webcast of the presentation will be available the following day in the Events section of the Company’s website, and as part of a complete catalog of presentations available at Noble Capital Markets’ Conference website and on Channelchek the investor portal created by Noble. The webcast will be archived on the Company's website, the NobleCon website, and Channelchek.com for 90 days following the event.
About Ocugen, Inc.
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe. We are making an impact on patients’ lives through courageous innovation—forging new scientific paths that harness our unique intellectual and human capital. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with a single product, and we are advancing research in infectious diseases to support public health and orthopedic diseases to address unmet medical needs. Discover more at www.ocugen.com and follow us on X and LinkedIn.
About Noble Capital Markets, Inc.
Established in 1984, Noble Capital Markets is an SEC / FINRA registered full-service investment bank and advisory firm with an award-winning research team and proprietary investor distribution platform. We deliver middle market expertise to entrepreneurs, corporations, financial sponsors, and investors. Over the past 40 years, Noble has raised billions of dollars for companies and published more than 45,000 equity research reports. Noble launched www.channelchek.com in 2018 - an investor community dedicated exclusively to public emerging growth and their industries. Channelchek is the first service to offer institutional-quality research to the public, for FREE at every level without a subscription. More than 7,000 public emerging growth companies are listed on the site, and content including equity research, webcasts, and industry articles.
Cautionary Note on Forward-Looking Statements
****This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.
Contact:
Tiffany Hamilton
Head of Communications
Tiffany.Hamilton@ocugen.com
FAQ
When is Ocugen (OCGN) presenting at NobleCon20?
Where can I watch Ocugen's (OCGN) NobleCon20 presentation?
What will Ocugen (OCGN) discuss at NobleCon20?
Where is NobleCon20 being held for Ocugen's (OCGN) presentation?
